Introductioṅ
Methods
Characteristic | Control group | HIIT group |
p value |
---|---|---|---|
n (men/women) | 8/3 | 10/2 | |
Age (years) | 59 ± 9 | 61 ± 9 | 0.70 |
Time since diagnosis (years) | 4 ± 2 | 5 ± 3 | |
BMI (kg/m2) | 32 ± 6 | 31 ± 5 | 0.71 |
Height (cm) | 169 ± 9 | 171 ± 8 | 0.71 |
Weight (kg) | 90 ± 9 | 90 ± 15 | 0.95 |
HbA1c (%) | 7 ± 0.5 | 7 ± 1 | 0.87 |
HbA1c (mmol/mol) | 55 ± 6 | 54 ± 11 | 0.88 |
Fasting glucose (mmol/l) | 7.0 ± 1.0 | 6.8 ± 1.6 | 0.69 |
2 h glucose (mmol/l) | 11.7 ± 3.1 | 12.5 ± 3.1 | 0.57 |
Liver fat (%) | 7.1 ± 6.8 | 6.9 ± 6.9 | 0.94 |
\( \dot{V}{\mathrm{O}}_{2\mathrm{peak}} \) (ml kg−1 min−1) | 20.3 ± 6.1 | 21.8 ± 5.4 | 0.54 |
Medications | |||
Metformin | 7 | 7 | |
Statins | 6 | 7 | |
BP | 5 | 3 |
Results
Parameter | Control | HIIT | Adjusted between-group p valueb
| ||||
---|---|---|---|---|---|---|---|
Pre | Post | Within-group p valuea
| Pre | Post | Within-group p valuea
| ||
Cardiac structure | |||||||
Left ventricular wall mass (g) | 107 ± 25 | 105 ± 25 | 0.54 | 104 ± 17 | 116 ± 20 | 0.02*
| 0.03†
|
Wall thickness systole (mm) | 5.5 ± 1.1 | 6.2 ± 1.0 | 0.01** | 6.2 ± 1.5 | 6.8 ± 1.1 | 0.07 | 0.54 |
Wall thickness diastole (mm) | 9.1 ± 2.5 | 10.1 ± 2.5 | 0.02* | 10.7 ± 3.1 | 11.5 ± 1.8 | 0.32 | 0.43 |
Eccentricity ratio (g/ml) | 0.85 ± 0.24 | 0.87 ± 0.18 | 0.66 | 0.94 ± 0.28 | 0.96 ± 0.24 | 0.70 | 0.66 |
End-diastolic volume (ml) | 129 ± 28 | 122 ± 28 | 0.08 | 118 ± 30 | 126 ± 30 | 0.01** | 0.00††
|
End-systolic volume (ml) | 50 ± 22 | 47 ± 22 | 0.33 | 42 ± 17 | 39 ± 13 | 0.25 | 0.76 |
Systolic function | |||||||
Systolic BP (mmHg) | 126 ± 3 | 124 ± 5 | 0.62 | 123 ± 4 | 122 ± 4 | 0.66 | 0.99 |
Diastolic BP (mmHg) | 84 ± 2 | 80 ± 2 | 0.07 | 81 ± 2 | 80 ± 2 | 0.81 | 0.41 |
Heart rate (bpm) | 63 ± 7 | 69 ± 13 | 0.21 | 67 ± 12 | 66 ± 16 | 0.69 | 0.27 |
Stroke volume (ml) | 79 ± 14 | 75 ± 15 | 0.16 | 76 ± 16 | 87 ± 19 | 0.00** | 0.00††
|
Cardiac output (l/min) | 5.0 ± 1.0 | 5.2 ± 1.0 | 0.54 | 5.0 ± 1.00 | 5.5 ± 1.0 | 0.07 | 0.31 |
Ejection fraction (%) | 64 ± 11 | 63 ± 10 | 0.62 | 65 ± 8 | 70 ± 6 | 0.02* | 0.03†
|
Longitudinal shortening (%) | 13.1 ± 2.2 | 12.7 ± 2.6 | 0.62 | 12.2 ± 3.0 | 13.4 ± 1.8 | 0.28 | 0.39 |
Diastolic function | |||||||
Early filling percentage (%) | 58 ± 11 | 59 ± 8 | 0.88 | 57 ± 9 | 60 ± 9 | 0.04* | 0.45 |
Early diastolic filling rate (ml/s) | 250 ± 44 | 251 ± 47 | 0.68 | 241 ± 84 | 299 ± 89 | 0.01** | 0.02†
|
Late diastolic filling rate (ml/s) | 310 ± 143 | 285 ± 60 | 0.68 | 278 ± 67 | 289 ± 64 | 0.53 | 0.56 |
Strain and torsion | |||||||
Peak endocardial circumferential strain (%) | 23.1 ± 4.1 | 23.4 ± 4.3 | 0.82 | 25.2 ± 4.6 | 24.5 ± 5.1 | 0.61 | 0.82 |
Peak whole wall circumferential strain (%) | 16.5 ± 3.1 | 16.0 ± 3.3 | 0.46 | 16.5 ± 3.1 | 16.4 ± 4.0 | 0.94 | 0.73 |
Peak torsion (°) | 7.1 ± 2.2 | 7.6 ± 1.9 | 0.19 | 8.1 ± 1.8 | 6.9 ± 1.6 | 0.04* | 0.04†
|
Metabolism | |||||||
PCr/ATP ratio | 1.76 ± 0.51 | 1.72 ± 0.36 | 0.80 | 1.74 ± 0.39 | 2.00 ± 0.36 | 0.19 | 0.12 |
Parameter | Control | HIIT | Adjusted between-group p valueb
| ||||
---|---|---|---|---|---|---|---|
Pre | Post | Within-group p valuea
| Pre | Post | Within-group p valuea
| ||
Body composition | |||||||
Weight (kg) | 90 ± 9 | 91 ± 10 | 0.06 | 90 ± 15 | 89 ± 15 | 0.09 | 0.02†
|
Fat mass (kg) | 35.6 ± 10.9 | 36.0 ± 11.3 | 0.36 | 31.9 ± 9.3 | 30.8 ± 10.2 | 0.09 | 0.08 |
Fat free mass (kg) | 54.3 ± 5.9 | 54.7 ± 5.7 | 0.28 | 57.7 ± 9.0 | 58.2 ± 8.9 | 0.34 | 0.72 |
Visceral adipose tissue (cm2) | 159 ± 58 | 156 ± 49 | 0.21 | 201 ± 80 | 181 ± 72 | 0.04* | 0.08 |
Liver fat (%) | 7.1 ± 6.8 | 7.7 ± 6.9 | 0.12 | 6.9 ± 6.9 | 4.2 ± 3.6 | 0.06 | 0.01††
|
Blood variables | |||||||
ALT (U/l) | 34 ± 16 | 33 ± 14 | 0.82 | 36 ± 11 | 30 ± 10 | 0.02* | 0.14 |
AST (U/l) | 27.6 ± 10.4 | 26.5 ± 8.8 | 0.63 | 27 ± 7 | 24 ± 6 | 0.02* | 0.25 |
ALP (U/l) | 59.2 ± 16.8 | 61.2 ± 17.5 | 0.09 | 66 ± 17 | 63 ± 16 | 0.10 | 0.03†
|
Total cholesterol (mmol/l) | 4.5 ± 0.9 | 4.6 ± 0.9 | 0.62 | 4.0 ± 1.0 | 4.5 ± 1.1 | 0.15 | 0.77 |
Triacylglycerol (mmol/l) | 1.1 ± 0.4 | 1.2 ± 0.4 | 0.12 | 1.1 ± 0.3 | 1.2 ± 0.4 | 0.28 | 0.87 |
Metabolic control | |||||||
HbA1c (%) | 7.2 ± 0.5 | 7.4 ± 0.7 | 0.07 | 7.1 ± 1.0 | 6.8 ± 0.9 | 0.10 | 0.02†
|
HbA1c (mmol/mol) | 54.9 ± 5.9 | 57.0 ± 7.5 | 0.06 | 54.5 ± 10.6 | 51.3 ± 10.2 | 0.09 | |
Fasting glucose (mmol/l) | 7.0 ± 1.0 | 7.6 ± 1.4 | 0.03* | 6.8 ± 1.6 | 6.8 ± 1.6 | 0.87 | 0.15 |
Fasting insulin (pmol/l) | 81.5 ± 46.4 | 88 ± 39.5 | 0.42 | 65.5 ± 39.5 | 65.5 ± 32.8 | 0.88 | 0.22 |
2 h glucose (mmol/l) | 11.7 ± 3.1 | 12.9 ± 2.7 | 0.01** | 12.5 ± 3.1 | 11.7 ± 3.1 | 0.22 | 0.02†
|
2 h AUGC | 1,366 ± 66 | 1,544 ± 86 | 0.01** | 1,395 ± 81 | 1,399 ± 87 | 0.94 | 0.02†
|
HOMA-IR | 1.6 ± 0.9 | 1.8 ± 0.8 | 0.40 | 1.3 ± 0.8 | 1.4 ± 0.6 | 0.94 | 0.19 |
HOMA2-β | 67.8 ± 31.4 | 67.0 ± 37.3 | 0.79 | 68.9 ± 48.6 | 70.9 ± 49.0 | 1.00 | 0.76 |
HOMA2-S | 76.1 ± 33.0 | 67.3 ± 29.5 | 0.25 | 101.7 ± 48.1 | 98.2 ± 53.8 | 0.88 | 0.39 |